KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.

Lu Sun, Lauren F Markus, Julio C Sanchez, Thomas J Lai, Eudocia Quant Lee, Gang Li, Jiyoon Kim, Zian Zhuang, Brenda Acevedo, Richard G Everson, Ingo K Mellinghoff, Elisa Aquilanti, L Nicolas Gonzalez Castro, J Ricardo McFaline-Figueroa, Lakshmi Nayak, Rameen Beroukhim, Robert A Chong, Jacqueline Stone, Thomas Kaley, Lauren Schaff, Jessica Wilcox, Catharina Westergaard, Alyssa Russ, Maria Lavallee, Ugonma Chukwueke, Annick D Van den Abbeele, Michael Lim, Benjamin M Ellingson, David A Reardon, Timothy F Cloughesy, Robert M Prins, Patrick Y Wen

Nat Commun 17(1) 10560

PMID42838943
PMCIDPMC13642311
DOI10.1038/s41467-026-77433-z
发表日期2026-10-06
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

We conducted a randomized surgical window-of-opportunity trial ( NCT04606316 ) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients received pre-surgical immune checkpoint blockade (ICB) with dual anti-PD1 nivolumab + anti-CTLA4 ipilimumab (Arm 1), nivolumab alone (Arm 2), or placebo (Arm 3). Following surgery, Arms 1 and 3 received dual ICB, while Arm 2 continued nivolumab until progression or unacceptable toxicity. The primary endpoint, tumor-infiltrating lymphocyte (TIL) density, was met for Arm 1, as neoadjuvant dual ICB significantly increased TIL density compared with untreated control (Arm 3). As a secondary endpoint, median overall survival in the ITT population was 402 days (95% CI, 265-571) among patients who received dual ICB (Arms 1 and 3) and 273 days (95% CI, 166-506) for those assigned to nivolumab alone (Arm 2). No unanticipated toxicities were observed. Exploratory analyses showed that dual ICB elicited robust intratumoral and systemic immune activation, including increased interferon-related gene expression in blood. Higher TIL density and early systemic interferon-signature induction were associated with improved survival, whereas tumor mutational burden was not. Our results demonstrate pharmacodynamic activity of dual ICB in glioblastoma, with survival outcomes comparing favorably to similar studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。